SRPK1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL407224	0.47	11/20
SCHEMBL422705	0.63	6/20
SCHEMBL425241	0.62	5/20
SCHEMBL422546	0.59	5/20
SCHEMBL422916	0.58	5/20
SCHEMBL425875	0.54	5/20
SCHEMBL408023	0.45	5/20
SCHEMBL234334	1.00	4/20
SCHEMBL423455	1.00	4/20
SCHEMBL423300	0.80	4/20
SCHEMBL419044	0.79	4/20
SCHEMBL421841	0.79	4/20
SCHEMBL422104	0.78	4/20
SCHEMBL423038	0.78	4/20
SCHEMBL425740	0.76	4/20
SCHEMBL423436	0.66	4/20
SCHEMBL421372	0.65	4/20
SCHEMBL421021	0.63	4/20
SCHEMBL425683	0.63	4/20
SCHEMBL423233	0.63	4/20

Clinical trials — most relevant to SRPK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI	PHASE1/PHASE2	UNKNOWN
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer	PHASE1/PHASE2	COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer	EARLY_PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
MicroRNA-1 (miRNA-1) and MicroRNA-133a (miRNA-133a) Levels After Acute Exercise in Ultimate Frisbee Athletes	nan	UNKNOWN
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Becker Muscular Dystrophy - A Natural History Study to Predict Efficacy of Exon Skipping	nan	UNKNOWN
Expression Pattern of HNRNPH1 and HNRNPK Genes in MPNs	nan	UNKNOWN
SRSF2 Gene Mutation in Patients With t-MDS/AML	nan	COMPLETED
Mechanisms of Cell Death in Spinal Muscular Atrophy	nan	COMPLETED
ADAR1 Expression Level in Rectal Cancer	nan	RECRUITING
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis	nan	COMPLETED
Patient's Derived Organoids for Drug Screening in Glioblastoma	nan	NOT_YET_RECRUITING
Molecular Disease Profile of Hematological Malignancies	nan	UNKNOWN
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact	nan	UNKNOWN
I-Tracking Neurodegeneration in Early Wolfram Syndrome	nan	COMPLETED
Transcriptomes Breast, Ovarian and Leukocyte Hereditary Genes Predisposing to Breast and / or Ovarian Cancer	nan	COMPLETED
Efficacy and Safety Study of EGCG/Tocotrienol in 18 Patients With Splicing-mutation-mediated Cystic Fibrosis (CF)	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SRPK1 binder may also engage these)

Protein	Name	Similarity
Q5RD27	—	1.000	Q5RD27 →
O70551	—	1.000	O70551 →
Q9Z1J2	—	0.995	Q9Z1J2 →
DYRK4	Dual specificity tyrosine-phosphorylation-regulated kinase 4	0.994	landscape →
Q9Z0G2	—	0.994	Q9Z0G2 →
Q68UT7	—	0.994	Q68UT7 →
P20689	—	0.993	P20689 →
Q8BI55	—	0.993	Q8BI55 →
Q92613	—	0.992	Q92613 →
Q8WML3	—	0.992	Q8WML3 →
B2GUY1	—	0.992	B2GUY1 →
Q6YY75	—	0.991	Q6YY75 →
Q9Z2U2	—	0.991	Q9Z2U2 →
O54781	—	0.991	O54781 →
Q6DFV7	—	0.991	Q6DFV7 →
Q63553	—	0.991	Q63553 →
Q8BZ21	—	0.991	Q8BZ21 →
Q6NZP1	—	0.990	Q6NZP1 →
Q4R8E0	—	0.990	Q4R8E0 →
SRPK2	SRSF protein kinase 2	0.990	landscape →
P27704	—	0.990	P27704 →
Q8C0X8	—	0.990	Q8C0X8 →
Q9Z2R9	—	0.990	Q9Z2R9 →
E1C2V1	—	0.989	E1C2V1 →
O54988	—	0.989	O54988 →
Q9FT70	—	0.989	Q9FT70 →
Q4R8X0	—	0.989	Q4R8X0 →
NEK11	Serine/threonine-protein kinase Nek11	0.989	landscape →
A6QP06	—	0.989	A6QP06 →
Q8N573	—	0.989	Q8N573 →